The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products Administration (NMPA), which has already approved the drug as a treatment for ...

Novartis Pharmaceuticals filed a lawsuit against the State of Rhode Island seeking to block the enforcement of a new state ...

Schuyler County is to receive a settlement from a New Jersey pharmaceutical company and its affiliates after the county argued it contributed to the ongoing opioid ...

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

The monoclonal antibody (mAb) helped maintain safe platelet levels for a prolonged period, reducing patient reliance on ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Novartis's Ianalumab Meets Goals in Phase 3 Trials to Treat Primary Immune Thrombocytopenia Novartis said its ianalumab drug combined with eltrombopag met the primary endpoint in a late-stage trial, ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

Gain insight on the investment environment in medical technology and healthcare, Novartis and more in the latest Market Talks ...